Angelica Gil

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer”.

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2024.7015

N/A

0.104DataRank · unranked

1 citations

Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno‐Aspitia +7 more

Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.529

N/A

0DataRank · unranked

0 citations

Angelica Gil, Yaohua Ma, Zhuo Li, Pooja Advani, Alvaro Moreno‐Aspitia +5 more